RhumbLine Advisers’s Cardiff Oncology CRDF Stock Holding History
Bought
Maintained
Sold
Other funds holding CRDF
RhumbLine Advisers's CRDF Position: Q3 2026 in Review
RhumbLine Advisers sold out of Cardiff Oncology (CRDF) in Q3 2026, closing a stake of 30,064 shares — an estimated $39.1K sold.
RhumbLine Advisers first reported a position in CRDF in Q2 2015 and held it in 21 quarters. The position peaked at $317K in Q3 2021. 75 funds tracked by Wall St. Rank hold CRDF as of Q3 2026.
- RhumbLine Advisers reported no remaining Cardiff Oncology position as of Q3 2026 after selling out during the quarter.
- RhumbLine Advisers sold 30,064 Cardiff Oncology shares in Q3 2026, an estimated $39.1K.
- RhumbLine Advisers first reported a position in Cardiff Oncology in Q2 2015 and held it in 21 quarters.
- RhumbLine Advisers's Cardiff Oncology position peaked at $317K in Q3 2021.
- 75 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2026.
Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.